pharmaceutical investing Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results
pharmaceutical investing Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School
Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016
Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting
Providence Gold Mines: Unlocking Untapped, High-grade Gold Deposits in the historic Mother Lode Gold Belt in California
